Quince Therapeutics
-88%
est. 2Y upside i
Rank
#4409
Sector
Healthcare
Est. Liquidity
~2Y
Data Quality
Data: MediumQuince Therapeutics presents an extremely high-risk equity opportunity for a job seeker.
Last updated: March 10, 2026
A highly successful reverse merger with a promising, well-funded private company leads to a combined entity valued at approximately $300M. After $247M in liquidation preferences, $53M is available for common shareholders. This represents a significant return for common stock from its current distressed valuation, reaching the maximum potential upside for the job seeker's equity package.
A reverse merger occurs, but the new entity struggles, or the terms are unfavorable. The combined entity is valued at approximately $100M. After $247M in liquidation preferences, common shareholders receive no value, leading to a near-total loss for the job seeker's equity.
Failure to secure a reverse merger leads to liquidation or bankruptcy (Chapter 7 or 11). Common shareholders receive no value due to the substantial liquidation preferences, resulting in a near-total loss of equity for the job seeker.
Preference Stack Risk
severeFunding Intensity
67%Total funding of $247M represents liquidation preferences that are approximately 42 times higher than the current market capitalization of ~$5.8M. Common shareholders are deeply underwater.
Dilution Risk
highFurther equity or debt issuance is highly likely to fund a reverse merger process or new operations, leading to significant dilution for existing common shareholders.
Secondary Liquidity
noneGiven the distressed state and low stock price, there is no active secondary market for Quince Therapeutics' equity.
Questions to Ask at the Interview
Strategic questions based on Quince Therapeutics's data — designed to show you've done your homework.
- 1
“Given the explicit warnings of potential liquidation and the significant cash burn, what is the concrete timeline and specific milestones for securing a reverse merger, and what are the contingency plans if a deal isn't reached within the next 6-12 months?”
- 2
“With $247M in total funding representing liquidation preferences and a current market cap of ~$5.8M, how does the company envision creating value for common shareholders in a reverse merger scenario, and what are the expected terms for existing common equity holders?”
- 3
“Following the failure of eDSP and the board resignations, what is the core strategic vision for the 'new' Quince Therapeutics post-reverse merger, and what specific assets or pipeline candidates would the acquiring company bring to justify a re-rating?”
Community
Valuation Sentiment
Our model estimates -88% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.